GlassScriptPhysician profile
Arun Sendilnathan
NPI 1013298223
$8,880.73
in general payments reported to CMS, 2019-2025
13 companies · $4,948 in 2025
The $4,948 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $141 · 2021: $53.38 · 2022: $2,877 · 2023: $210 · 2024: $313 · 2025: $4,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,500 · Travel and Lodging: $1,771 · Food and Beverage: $1,184 · Education: $16.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,500.00 |
| Travel and Lodging | $1,771.05 |
| Food and Beverage | $1,183.78 |
| Education | $16.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $4,639.67 | 2025 | Cabometyx |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $1,340.34 | 2021-2025 | Clonoseq |
| Tempus Ai, INC | $273.90 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $252.02 | 2019-2023 | Opdivo |
| Abbvie INC. | $216.94 | 2024-2025 | |
| Genzyme Corporation | $159.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2020 | |
| Celgene Corporation | $120.65 | 2019 | |
| Merck Sharp & Dohme LLC | $119.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $71.77 | 2023 | |
| Dendreon Pharmaceuticals LLC | $49.23 | 2024 | Provenge |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Sendilnathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.